Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI: Insights From the PROSPECT II TrialClinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
University of Copenhagen, Copenhagen, Denmark.
Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
Department of Cardiology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
Division of Cardiology, University of California San Diego, San Diego, California, USA.
Department of Cardiology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden.
Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway.
Department of Cardiology, Odense University Hospital, Odense, Denmark.
Department of Clinical Science, University of Bergen, Bergen, Norway.
Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway.
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden.
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
Department of Medical Sciences and Cardiology, Uppsala University and Uppsala Clinical Research Center, Uppsala, Sweden.
New York-Presbyterian Hospital and Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.
Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
Show others and affiliations
2025 (English)In: JACC: Cardiovascular Interventions, ISSN 1936-8798, E-ISSN 1876-7605Article in journal (Refereed) Epub ahead of print
Abstract [en]
BACKGROUND: Inflammation is a driver of atherosclerosis and susceptibility to cardiovascular events. OBJECTIVES: The authors sought to evaluate whether high-sensitivity C-reactive protein (hsCRP) levels are associated with the prevalence of high-risk coronary plaques in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
METHODS: PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II was a multicenter, prospective study enrolling patients with recent myocardial infarction. Following treatment of all flow-limiting lesions, 3-vessel imaging with near-infrared spectroscopy and intravascular ultrasound was used to characterize untreated nonculprit lesions. We investigated the association between baseline hsCRP and plaque morphology (lipid content, plaque burden, lumen area) in 501 NSTEMI patients. hsCRP levels were categorized as low (<1 mg/L), intermediate (1-3 mg/L), or high (>3 mg/L).
RESULTS: The percentages of patients with at least 1 highly lipidic plaque (maximum lipid core burden index for any 4-mm pullback length ≥324.7) increased from 39.4% to 57.2% to 59.3% in the low, intermediate, and high hsCRP groups, respectively (P = 0.01). The proportion of patients with at least 1 highly lipidic plaque with ≥70% burden increased with hsCRP levels from 22.7% to 27.2% to 36.7%, respectively (P = 0.01). Multivariable analyses showed that increasing hsCRP was associated with higher total coronary artery lipid core burden index and plaque volume. Higher hsCRP increased the odds of having any highly lipidic plaque and those with ≥70% plaque burden.
CONCLUSIONS: Among patients with recent NSTEMI, a high baseline hsCRP level was associated with the presence of pan-coronary atherosclerosis and focal high-risk plaques. (PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial; NCT02171065).
Place, publisher, year, edition, pages
Elsevier, 2025.
Keywords [en]
Atherosclerosis, cardiovascular event(s), coronary plaques, inflammation, intravascular ultrasound, myocardial infarction, near-infrared spectroscopy, non–ST-segment elevation myocardial infarction
National Category
Autoimmunity and Inflammation Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-120817DOI: 10.1016/j.jcin.2025.01.440PubMedID: 40272345OAI: oai:DiVA.org:oru-120817DiVA, id: diva2:1954870
2025-04-282025-04-282025-04-28Bibliographically approved